Modified de Gramont Regimen for Colorectal Cancer
Author Information
Author(s): Cheeseman S L, Joel S P, Chester J D, Wilson G, Dent J T, Richards F J, Seymour M T
Primary Institution: Cancer Research UK Clinical Centre in Leeds
Hypothesis
Can a simplified 'Modified de Gramont' regimen improve the treatment of advanced colorectal cancer while maintaining efficacy and reducing toxicity?
Conclusion
The Modified de Gramont regimen is convenient, well-tolerated, and shows promising efficacy in treating advanced colorectal cancer.
Supporting Evidence
- Objective responses in colorectal cancer patients were observed with the Modified de Gramont regimen.
- Grade 3-4 toxicity was rare with the OxMdG regimen.
- Two deaths were associated with treatment, highlighting the need for careful monitoring.
Takeaway
Doctors created a simpler way to give medicine to cancer patients that works just as well and is easier for them to handle.
Methodology
Patients received either the Modified de Gramont regimen or the Modified de Gramont plus oxaliplatin regimen, with dose escalation to determine optimal fluorouracil doses.
Potential Biases
Potential bias in patient selection and reporting of outcomes due to the non-randomized design.
Limitations
The study was not designed to measure efficacy formally, and the sample size for some analyses was small.
Participant Demographics
Patients included 46 with advanced gastrointestinal cancer and 62 with colorectal cancer, with some being unpretreated and others fluorouracil-resistant.
Statistical Information
P-Value
0.0004
Confidence Interval
95% CI for response rate 50–88%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website